Combination of Pertuzumab and Erlotinib as 2nd-/3rd-Line (2/3L) Treatment for Patients (pts) With Metastatic Non-Small Cell Lung Cancer (NSCLC) - Safety and Anti-Tumour Activity by FDG-PET/CT Imaging Changes

被引：0
|
作者：
Hughes, B. [1 ]
Mileshkin, L. [2 ]
Townley, P. [3 ]
Gitlitz, B. [4 ]
Eaton, K. [5 ]
Mitchell, P. [6 ]
Hicks, R. [2 ]
Loecke, D. [7 ]
Amler, L. [7 ]
Pirzkall, A. [7 ]
机构：
[1] Royal Brisbane & Womens Hosp, Canc Care Serv, Brisbane, Qld, Australia
[2] Peter MacCallum Canc Ctr, Div Haematol & Med Oncol, Melbourne, Vic, Australia
[3] Nebraska Canc Specialists, Methodist Estabrook Canc Ctr, Omaha, NE USA
[4] Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[5] Univ Washington, Med Ctr, Dept Internal Med, Seattle, WA 98195 USA
[6] Austin Hosp, Ludwig Med Oncol Dept, Melbourne, Vic 3084, Australia
[7] Genentech Inc, BioOncol, San Francisco, CA 94080 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)72431-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S629 / S629
页数：1
相关论文
共 50 条
  • [31] Durvalumab in treatment-naive, stage IV non-small cell lung cancer (NSCLC) patients (pts), with ECOG performance status (PS) 2-3 and high PD-L1 tumour expression: Results of IFCT-1802 SAVIMMUNE phase II trial
    Gounant, V.
    Greillier, L.
    Mascaux, C.
    Pinquie, F.
    Carmier, D.
    Moreau, L.
    Roch, B.
    Debieuvre, D.
    Dhalluin, X.
    Giroux-Leprieur, E.
    Berton, E.
    Rabeau, A.
    Raimbourg, J.
    Dixmier, A.
    Naltet, C.
    Khalil, A.
    Ezzeddine, L.
    Langlais, A.
    Morin, F.
    Duruisseaux, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S842 - S842
  • [32] Erlotinib plus ramucirumab (RAM) as first-line treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation: phase 1B safety results and Phase 3 design of the ongoing Phase 1B/3 study RELAY
    Bischoff, H.
    Garon, E. B.
    Lee, P.
    He, S.
    Kropf-Sanchen, C.
    Kimmich, M.
    Nakagawa, K.
    Reck, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 171 - 171
  • [33] First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non-small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA.
    Paz-Ares, Luis G.
    Ciuleanu, Tudor-Eliade
    Cobo-Dols, Manuel
    Bennouna, Jaafar
    Cheng, Ying
    Mizutani, Hideaki
    Lingua, Alejo
    Reyes, Felipe
    Reinmuth, Niels
    De Menezes, Juliana Janoski
    Jassem, Jacek
    Protsenko, Svetlana
    Feeney, Kynan
    Jimenez, Emmanuel De La Mora
    Lu, Shun
    John, Tom
    Carbone, David Paul
    Zhang, Xiaoqing
    Hu, Nan
    Reck, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
  • [34] High incidence of symptomatic methemoglobinemia (metHb) in Asian patients (pts) treated with 3-Aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, triapine) and gemcitabine (GEM) in a second-line phase II trial of metastatic non-small cell lung cancer
    Ma, B.
    Tan, E. H.
    Mok, T.
    Lam, K. C.
    Soo, R.
    Leong, S. S.
    Wang, L. Z.
    Mo, F.
    Chan, A. T.
    Goh, B. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [35] Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03
    Planchard, D.
    Brahmer, J. R.
    Yang, J. C-H.
    Kim, H. R.
    Li, R. K.
    Han, J-Y.
    Cortinovis, D. L.
    Runglodvatana, Y.
    Nakajima, E.
    Ragone, A.
    Winter, M.
    Gustavson, M.
    ANNALS OF ONCOLOGY, 2023, 34
  • [36] Phase I study of BI 754111 (anti-LAG-3) plus BI 754091(anti-PD-1) in patients (pts) with advanced solid cancers, followed by expansion in pts with microsatellite stable metastatic colorectal cancer (mCRC), anti-PD-(L)1-pretreated non-small cell lung cancer (NSCLC) and other solid tumors
    Johnson, M. L.
    Patel, M. R.
    Ulahannan, S. V.
    Hansen, A.
    George, B.
    Chu, Q. S-C.
    Elgadi, M.
    Ge, M.
    Duffy, C.
    Graeser, R.
    Khedkar, S.
    Jones, S. F.
    Burris, H.
    ANNALS OF ONCOLOGY, 2018, 29
  • [37] Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients.
    Fong, Lawrence
    Forde, Patrick M.
    Powderly, John D.
    Goldman, Jonathan Wade
    Nemunaitis, John J.
    Luke, Jason John
    Hellmann, Matthew David
    Kummar, Shivaani
    Doebele, Robert Charles
    Mahadevan, Daruka
    Gadgeel, Shirish M.
    Hughes, Brett Gordon Maxwell
    Markman, Ben
    Riese, Matthew John
    Brody, Joshua
    Emens, Leisha A.
    McCaffery, Ian
    Miller, Richard Alan
    Laport, Ginna
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [38] Activity and toxicity in pulmonart: Involved-field 3D radiotherapy (RT) and docetaxel/cisplatin chemotherapy (CT) in a randomised phase 2 study comparing concurrent CT-RT followed by consolidation CT, with induction CT followed by concurrent CT-RT in patients (PTS) with stage III non-small cell lung cancer (NSCLC)
    van Meerbeeck, Jan P.
    Senan, Suresh
    Cardenal, Felipe
    Vansteenkiste, Johan
    Stigt, Jos
    Akyol, Fadil
    Chaltin, Marie
    Bakker, Joke
    Du Pont, Jean Michel
    Scagliotti, Giorgio V.
    ANNALS OF ONCOLOGY, 2006, 17 : 213 - 213
  • [39] Subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase 3 study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC)
    Reck, M.
    Paz-Ares, L.
    Perol, M.
    Johnson, M.
    Pennell, N.
    Novello, S.
    Cappuzzo, F.
    Bidoli, P.
    Zimmermann, A.
    Lee, P.
    Sashegyi, A.
    Varea Menendez, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [40] A phase Ib dose-escalation study evaluating trastuzumab deruxtecan (T-DXd) and durvalumab in combination with chemotherapy as first-line treatment in patients with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (DESTINY-Lung03)
    Planchard, D.
    Yang, J. C-H.
    Brahmer, J. R.
    Ragone, A.
    Chen, J.
    Liu, F.
    Saggese, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S798 - S798
12345